Recombinant human
endostatin (
Endostar) plus
vinorelbine/
cisplatin (NP) had been approved for the treatment of non-small cell
lung cancers (NSCLC). But the real-world treatment pattern and effectiveness of
Endostar plus other
combination chemotherapy, namely
docetaxel/
platinum (DP),
gemcitabine/
platinum (GP),
pemetrexed/
platinum (PP), and
paclitaxel/
platinum (TP) in both treatment-naïve and re-treatment patients with advanced NSCLC were still unclear. A retrospective observational study was conducted based on the electronic medical record (EMR) system and advanced patients with NSCLC were identified from 7 cancer hospitals in China from 2012 to 2019. These patients were divided into five groups,
Endostar plus NP,
Endostar plus DP,
Endostar plus GP,
Endostar plus PP, and
Endostar plus TP groups. The disease control rate (DCR), overall response rate (ORR), and the progression-free survival (PFS) were evaluated. Of the eligible 512 advanced patients with NSCLC, 10.35% were in
Endostar plus NP group, while the numbers were 15.43%, 32.42%, 26.56%, 15.23% in
Endostar plus DP group,
Endostar plus GP group,
Endostar plus PP group, and
Endostar plus TP group, respectively. The ORRs were 31%, 28%, 22%, 41% and 27%, and the DCRs were 71%, 72%, 57%, 72% and 76%, respectively. The median of PFSs for the above groups were 7.9, 6.8, 5.6, 13.7, and 5.4 months. Compared with
Endostar plus NP group, the hazard ratios (HRs) and 95%CIs of
Endostar plus other
chemotherapy were 1.86 (0.75-4.61), 2.15 (0.83-5.60), 1.33 (0.51-3.44), and 2.42 (0.86-6.81). This real-world study found the effectiveness of
Endostar plus DP,
Endostar plus GP,
Endostar plus PP, and
Endostar plus TP were of no statistically significant differences compared with
Endostar plus NP and reflected the good effectiveness of
Endostar plus different
chemotherapy in advanced patients with NSCLC.